Regenxbio Expected to Report 70% Revenue Drop, $1.34 Loss Per Share
RGNX sits 52% above its 52-week low of $6.89.
Summary
Regenxbio Inc is expected to report a significant loss of $1.34 per share and a 70.4% decrease in quarterly revenue to $26.322 million for the period ending March 31, 2026. This earnings preview, based on analyst estimates, highlights a deteriorating financial outlook, with the mean earnings estimate having fallen by 5.2% in the last three months. This news reinforces concerns about the company's financial stability, especially following its recent 10-K filing which raised substantial doubt about its ability to continue as a going concern and noted critical FDA setbacks for its gene therapies. The expected substantial revenue decline, coupled with the existing highly dilutive ATM offering, suggests continued pressure on the company's financials. Traders will be closely watching the actual earnings release on May 14 for confirmation of these trends and any further commentary on the company's operational and financial health.
At the time of this announcement, RGNX was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $537.9M. The 52-week trading range was $6.89 to $16.19. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.